- Home
- PFX vs ATRA Comparison
PFX vs ATRA Comparison
Compare PFX & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFX
- ATRA
- Stock Information
- Founded
- PFX 2010
- ATRA 2012
- Country
- PFX United States
- ATRA United States
- Employees
- PFX N/A
- ATRA N/A
- Industry
- PFX Finance: Consumer Services
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFX Finance
- ATRA Health Care
- Exchange
- PFX Nasdaq
- ATRA Nasdaq
- Market Cap
- PFX 96.4M
- ATRA 99.1M
- IPO Year
- PFX N/A
- ATRA 2014
- Fundamental
- Price
- PFX $42.44
- ATRA $15.14
- Analyst Decision
- PFX
- ATRA Strong Buy
- Analyst Count
- PFX 0
- ATRA 3
- Target Price
- PFX N/A
- ATRA $21.00
- AVG Volume (30 Days)
- PFX 1.8K
- ATRA 68.5K
- Earning Date
- PFX 12-16-2025
- ATRA 11-12-2025
- Dividend Yield
- PFX 3.37%
- ATRA N/A
- EPS Growth
- PFX N/A
- ATRA N/A
- EPS
- PFX 3.06
- ATRA 1.97
- Revenue
- PFX $23,958,590.00
- ATRA $151,930,000.00
- Revenue This Year
- PFX $10.24
- ATRA N/A
- Revenue Next Year
- PFX N/A
- ATRA N/A
- P/E Ratio
- PFX $13.88
- ATRA $7.56
- Revenue Growth
- PFX 7.47
- ATRA 51.27
- 52 Week Low
- PFX $41.00
- ATRA $5.01
- 52 Week High
- PFX $57.40
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- PFX 39.13
- ATRA 58.23
- Support Level
- PFX $41.00
- ATRA $12.93
- Resistance Level
- PFX $43.00
- ATRA $15.12
- Average True Range (ATR)
- PFX 0.67
- ATRA 1.06
- MACD
- PFX 0.15
- ATRA 0.23
- Stochastic Oscillator
- PFX 55.82
- ATRA 91.37
About PFX PhenixFIN Corporation
PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).